Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Cogent Biosciences (COGT) EBIT (2017 - 2021)

Cogent Biosciences has reported EBIT over the past 5 years, most recently at -$25.6 million for Q4 2021.

  • Quarterly results put EBIT at -$25.6 million for Q4 2021, down 123.81% from a year ago — trailing twelve months through Dec 2021 was -$75.6 million (up 8.09% YoY), and the annual figure for FY2025 was -$333.4 million, down 20.81%.
  • EBIT for Q4 2021 was -$25.6 million at Cogent Biosciences, down from -$19.8 million in the prior quarter.
  • Over the last five years, EBIT for COGT hit a ceiling of $2.2 million in Q4 2019 and a floor of -$57.2 million in Q3 2020.
  • Median EBIT over the past 5 years was -$10.0 million (2018), compared with a mean of -$12.6 million.
  • Biggest five-year swings in EBIT: surged 124.88% in 2019 and later plummeted 611.43% in 2020.
  • Cogent Biosciences' EBIT stood at -$6.9 million in 2017, then plummeted by 30.87% to -$9.0 million in 2018, then surged by 124.88% to $2.2 million in 2019, then plummeted by 611.43% to -$11.5 million in 2020, then tumbled by 123.81% to -$25.6 million in 2021.
  • The last three reported values for EBIT were -$25.6 million (Q4 2021), -$19.8 million (Q3 2021), and -$17.3 million (Q2 2021) per Business Quant data.